Biocon stock soars 4% after USFDA clears Malaysia unit, ends regulatory hurdles
Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and launch of its insulin biosimilar drug--Aspart.
Biocon share price jumps over 4% after US FDA clears Malaysian insulin facility
Biocon share price rose 4.5% following US FDA clearance for its Malaysian insulin facility, resolving a regulatory bottleneck. Bank of America raised its price target by 9% to ₹435, reflecting ...
FDA Changes Food Safety Protocol for Fresh and Frozen Berries
The FDA just announced changes to help make berries sold in the U.S. safer to eat, lowering the odds you’ll get norovirus or ...
Biocon shares surge over 4% after Malaysia unit gets clearance from the USFDA
Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated. This followed an inspection conducted in September 2024. BofA maintained its ...
Malaysia Sun14d
BMI revises up Malaysian ringgit forecast for 2025
BMI Country Risk and Industry Research has revised its Malaysian ringgit forecast and expected the ringgit to appreciate from 4.50 ringgits against ...
tnp.straitstimes29d
Slimming craze in Malaysia deprives diabetics of Ozempic
The global craze over Ozempic as a weight-loss solution has hit Malaysia, with pharmacies experiencing a surge in demand for ...